Tag: VICL

Blue Horseshoe Stocks: ECYT Recap & More

Endocyte, Inc. ECYT

We took notice of ECYT yesterday morning during our routine premarket scan, and due to some abnormal activity, we decided to include it in the daily watchlist.

It turned out to be a splendid idea, with the stock ultimately recording a hugely bullish session. ECYT traded from its low of 1.63 just following the open, to its high of 3.75 just prior to the close. It worked out to a single-session rip of 130% and it came on over 180X the monthly average volume. The stock has also hit a new high of 6.07 in the premarket this morning, pushing our observed move in less than 24 hours to a whopping 272%

It was especially impressive because of the timing, which couldn’t have been any better. Prior to yesterday’s session the stock was stagnating for several months. The move was catalyzed primarily by the announcement of the completion of a worldwide license on the company’s prostate cancer treatment, which will be moving on to Phase III development. (>>View PR)

Rigel Pharmaceuticals, Inc. RIGL

Speaking of solidly-timed calls on pharma plays, we also caught RIGL and included it in yesterday’s premarket report. It didn’t see the type of move that the previously mentioned stock, but got off to a respectable start.

RIGL traded in a range from 2.85-3.42, a modest rise of 20%, but did so on nearly 17X the monthly average volume, and closed near its high of day. We’ll continue to observe this play to see if it can establish a sustained uptrend.

Capricor Therapeutics, Inc. CAPR

We were just updating our readers yesterday morning on the moves CAPR had made since we had alerted it onSeptember 20th from its low of 1.80.

What followed was another nice session for the stock, which ran to a new high of 4.25; a total increase of 136% in a span of just eight trading days.


Tiffany & Co. TIF – Options Update

We also want to quickly update readers on our TIF options ideas that we submitted on the morning of September 28th, the TIF 10/20 $92-93 Calls. The stock has been in a continuous bullish pattern since then, and those calls made some pretty nice gains in the process.

$92 Calls – Range: 1.00-2.13 – Max Gain: 113%
$92.50 Calls – Range: .85-1.74  – Max Gain: 105%.
$93 Calls – Range: .83-1.88 – Max Gain: 127%

Extended Watchlist:
ETRM, VICL, DMPI, TA, KOOL, CATB

Blue Horseshoe Stocks: IMGN, AURI Reviews & More

ImmunoGen, Inc. IMGN

We were hoping for a strong start to the week yesterday, and IMGN was among those stocks to provide us with the spark to get it going. We tagged this play in yesterday’s extended watchlist after noticing it gapping up pretty heavily in the premarket.

From its opening price of 11.48, the stock soared as high as 15.88, a single session spike of 38% on volume that exceeded the 3-month average by more than ten times.

We’ll always continue to keep watch over a stock on the tail-end of such a momentous burst, as there may be rebound opportunities presenting themselves on any pullbacks.

Auri, Inc. AURI

Speaking of bounceplays, AURI ended up turning in an impressive intraday performance yesterday. Just as we were patting ourselves on the back for catching a 92% pop in the stock on Friday, we explicitly suggested that there could be added opportunities forthcoming, stating:

“We won’t disregard the possibility of a bounceplay once the stock establishes firm support, so we’ll be on the lookout for that.”

We didn’t have to keep a lookout for long, because after dipping down to find support at .003 quite early in the session, the stock banged out another huge move for us, running all the way up to .0064. That marked an intraday swing of 113% and occurred on nearly three times the monthly average volume.

We’ll keep our eyes on the price action as the week progresses, being interested to see how this morning’s publications of New Shareholder Updates & Current Status and new sales distribution channels are received.

Oncothyreon, Inc. ONTY

We also flagged ONTY in yesterday’s report, and it made a notable intraday move as well. The stock traded in a range from 3.78-4.69, providing folks with the chance at modest intraday gains of up to 24%

Our timing in re-alerting this play yesterday was beautiful, as the daily high also registered as a new 52-week high. When calculated from our observed low of 2.80 following our initial alert on the stock on May 22nd, it comes in at an overall increase of 67% in just over a week’s time.

DirectView Holdings, Inc. DIRV

As we’re all aware, 2015 has been a year of heightened tensions between civilians and law enforcement, showing the growing need for more oversight into police operations. We successfully used the beginning of this trend to trade TASR options earlier this year, and we’re going to radar DIRV as a similar type of play in the microcap arena .

Like TASR, the company produces body-worn cameras, the implementation of which has been an exponentially growing trend in cities across the country this year. This morning we learned that the company has been testing on a special line of the products that includes mobile broadband technology. >> READ PR

In addition, DIRV is building a cherry of a chart at the moment, as we point out with the annotations below. We’ll place it on our watchlist moving forward.

PLUG Power, Inc PLUG

We recently rementioned an old favorite, PLUG, and said that we wanted to see it get back  to trading above its 50DMA and the stock has done that. It has been doing a good job of holding support above that mark (Currently 2.61) and we wanted to point out the PR that hit the wires this morning.

Extended Watchlist:
AVEO, VICL, CDTI, XGTI, OHGI

DCTH, ZLCS & Extended Watchlist

Delcath Systems, Inc.  DCTH
Following its inclusion in yesterday morning’s extended watchlist, DCTH would go on to have a massively successful day of trading. The stock, after briefly touching a bottom at the .402-mark, went on an absolute tear as it reached a high .66 around lunchtime.

A single-session gain of 64% on the first day we placed DCTH on our watchlist is certainly nothing to sneeze at, and given the circumstances behind the upward surge, that may have only been the beginning.

The company received word from the FDA that its Primary Liver Disease treatment, ChemoSat, had received “orphan drug” designation, a classification which denotes a drug or procedure that is aimed at a disease which affects less than 200,000 people. About 26,000 Americans are diagnosed with Primary Liver Disease each year.

(Thomson Reuters ONE via COMTEX) — New York, NY – October 1, 2013 – Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company orphan drug designation for melphalan in the treatment of patients with hepatocellular carcinoma (HCC, or primary liver cancer). >>>FULL STORY

Side Note:
We rarely see stocks in this price range with an active options chain, but DCTH is an exception. The 12/21 .50 Calls jump out at us at first glance. If the stock were to approach a dollar between now and the expiration date, one could be looking at triple-digit gains.

Zalicus, Inc. ZLCS

Coincidentally, ZLCS, a stock that we’ve been following since the beginning of last month, also received a recent FDA orphan drug designation for its experimental Z160 drug, intended for the treatment of pain related to the Shingles.

Hitting a high of 1.38 yesterday, we finally saw ZLCS fill the gap on the chart that we had been pointing out for some time. Since we’ve been following ZLCS, we’ve seen a low of .78, and yesterday’s high represents a 77% gain off of that bottom. The filling of that gap was a pretty good indicator that it was time to take profits off of the table, so we certainly hope that folks were able to take advantage.

This morning, they also announced a reverse split, the result of which should be the stocks continued listing on the Nasdaq Capital Market, as it should enable shares to remain above the 1.00 minimum bid price required for listing. We would expect shares to come away from this split valued in the $6.00-range, and sure enough, we are seeing trades go off as high as 6.45 pre-market.

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock, effective as of October 3, 2013 at 12:01 a.m. Eastern Time…The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 147.5 million to approximately 24.6 million. >>> FULL STORY

Extended Watchlist:

VICL, CRRS, CIMT, MNTG, RNN, MSTX